A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 36
- Population
- ALL · 45 Years to 80 Years
- Duration
- 2017-10-18 to 2018-11-01
- Intervention
- TK001
- Comparator
- Not reported
- Outcomes measured
- Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001 in t…; Area under the plasma concentration-time curve (AUC) — 12 weeks; Maximum plasma concentration (Cmax) — 12 weeks; Time to reach maximum concentration (Tmax) — 12 weeks; Elimination half-Life (T½) — 12 weeks; Change from baseline in the Best Corrected Visual Acuity at 12 weeks — 12 weeks; Change from baseline in the mean central retinal thickness at 12 weeks — 12 weeks; Change from baseline in the thickness of choroidal neovascularization at 12 weeks — 12 weeks; Change from baseline in the retinal thickness in the site of lesion which was the thickest at 12 weeks — 12 weeks; Change from baseline in macular volume at 12 weeks — 12 weeks; Change from baseline in the area of choroidal neovascularization at 12 weeks — 12 weeks; Change from baseline in the area of leakage at 12 weeks — 12 weeks; Change from baseline in the total lesion size at 12 weeks — 12 weeks; Percentage of Participants Positive for anti-TK001 antibody at 12 weeks — 12 weeks; Change from baseline in the Best Corrected Visual Acuity at 52 weeks — 40 weeks; Change from baseline in the mean central retinal thickness at 52 weeks — 40 weeks; Change from baseline in the thickness of choroidal neovascularization at 52 weeks — 40 weeks; Change from baseline in the retinal thickness in the site of lesion which was the thickest at 52 weeks — 40 weeks; Change from baseline in macular volume at 52 weeks — 40 weeks; Change from baseline in the area of choroidal neovascularization at 52 weeks — 40 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.